S'abonner

Long-term outcomes of stereotactic ablative body radiotherapy for primary kidney cancer (TROG 15.03 FASTRACK II): a multicentre, non-randomised, phase 2 study - 02/06/26

Doi : 10.1016/S1470-2045(26)00091-4 
Shankar Siva, ProfMBBS PhD a, b, ⁎ , David Pryor, MBBS c, Jarad Martin, ProfPhD DMed d, Nicholas Hardcastle, PhD a, Daniel Moon, MBBS a, e, Tomas Kron, ProfPhD a, b, f, Braden Higgs, MBBS g, Farshad Foroudi, ProfMBBS DMedSc h, i, Jeremy Ruben, MbBCh Mmed j, Swetha Sridharan, MBBS d, Rebecca Montgomery, BBiomedSc k, Ryan Davey, PhD k, Charles Lin, MBBS l, m, Mark Shaw, MB ChB a, b, Nathan Lawrentschuk, ProfMBBS PhD a, e, Sree Appu, MBBS n, Ben G L Vanneste, MD PhD o, p, Michael S Hofman, ProfMBBS a, Declan G Murphy, ProfMB BCh a, b, Richard De Abreu Lourenco, ProfPhD q, Pascal Mancuso, MBBS r, Nicholas R Brook, MD g, s, Avi Raman, MBBS MPH t, u, Lih-Ming Wong, MBBS DMedSci e, v, Mark Sidhom, MBBS w, x, Simon Wood, MBBS c, Muhammad Ali, MBBS a, b, Mathias Bressel, MSc a, b
a Peter MacCallum Cancer Centre, Melbourne, VIC, Australia 
b Sir Peter MacCallum Department of Oncology, University of Melbourne, VIC, Australia 
c Princess Alexandra Hospital, Brisbane, QLD, Australia 
d Calvary Mater Newcastle, Waratah, NSW, Australia 
e Department of Surgery, University of Melbourne, Melbourne, VIC, Australia 
f Centre of Medical Radiation Physics, University of Wollongong, Wollongong, NSW, Australia 
g Royal Adelaide Hospital, Adelaide, SA, Australia 
h Monash University, Melbourne, VIC, Australia 
i Olivia Newton-John Cancer Centre, Melbourne, VIC, Australia 
j Alfred Health, Melbourne, VIC, Australia 
k TransTasman Radiation Oncology Group Cancer Research, Newcastle, NSW, Australia 
l University of Queensland, Brisbane, QLD, Australia 
m Royal Brisbane and Women’s Hospital, Brisbane, QLD, Australia 
n Cabrini Research Division, Melbourne, VIC, Australia 
o MAASTRO clinic, Maastricht, Netherlands 
p Department of Radiation Oncology, Ghent University Hospital, Ghent, Belgium 
q Centre for Health Economics Research and Evaluation, University of Technology Sydney, Sydney, NSW, Australia 
r Liverpool Hospital, Sydney, NSW, Australia 
s Adelaide Medical School, The University of Adelaide, Adelaide, SA, Australia 
t John Hunter Hospital, Newcastle, NSW, Australia 
u University of Newcastle, Newcastle, NSW, Australia 
v Department of Urology, St Vincent’s Health, Melbourne, VIC, Australia 
w Department of Radiation Oncology, Liverpool Cancer Therapy Services, Sydney, NSW, Australia 
x South West Sydney Clinical School, University of New South Wales, Sydney, NSW Australia 

* Correspondence to: Prof Shankar Siva, Peter MacCallum Cancer Centre, Melbourne 3000, VIC, Australia Peter MacCallum Cancer Centre Melbourne VIC 3000 Australia

Summary

Background

Stereotactic ablative body radiotherapy (SABR) is an emerging, non-invasive alternative for primary renal cell carcinoma. We aimed to provide the final long-term trial outcomes of TransTasman Radiation Oncology Group (TROG) 15.03 FASTRACK II, the first phase 2 trial investigating SABR for primary renal cell carcinoma to our knowledge.

Methods

FASTRACK II was a non-randomised, phase 2 study conducted in eight hospitals in Australia and the Netherlands by TROG and the Australian and New Zealand Urogenital and Prostate (ANZUP) Cancer Trials Group. Here, we report the final pre-planned follow-up results. Adult patients (aged ≥18 years) with histologically confirmed primary renal cell carcinoma, who were medically inoperable, high risk, or declined surgery, had an Eastern Cooperative Oncology Group performance status of 2 or less, had tumours 10 cm or less in size, and had N0–N1 disease were included. Patients underwent either a single fraction SABR of 26 Gy for tumours 4 cm or less in maximum diameter, or 42 Gy in three fractions delivered 48 h apart for tumours more than 4 cm in maximum diameter. The primary outcome was freedom from local progression to assess local control after SABR evaluated with the Response Evaluation Criteria in Solid Tumours. The primary endpoint and safety were evaluated in the intention-to-treat population. A patient representative was involved in the study design and conduct. The trial was registered with ClinicalTrials.gov ( NCT02613819 ) and is closed to enrolment.

Findings

Between July 28, 2016, and Feb 27, 2020, 71 patients were enrolled and one withdrew consent before treatment. Median follow-up was 62 months (IQR 60–72), median age was 77 years (70–82). 49 (70%) of 70 patients were male and 21 (30%) were female. Race and ethnicity data were not collected. The median tumour size was 46 mm (37–55), with 24 (34%) patients with T1a disease, 39 (56%) with T1b disease, six (9%) with T2a disease, and one (1%) with T3a disease. One patient (1%) had nodal involvement (N1). SABR resulted in 100% local control at 36 months, 60 months, and 84 months. Seven (10%) patients had at least one grade 3 adverse event within 9 months of SABR that was designated possibly, probably, or definitely related to treatment: nausea and vomiting (three [4%] events); abdominal, flank, or tumour pain (four [6%]); colonic obstruction (two [3%]); and diarrhoea (one [1%]). No new long-term safety signals, grade 4 events, or treatment-related deaths were noted.

Interpretation

Long-term follow-up supports the safety and local control of SABR for non-surgical patients with renal cell carcinoma, with no observed local recurrences or cancer-related deaths in this cohort, which had predominantly T1b disease or higher.

Funding

The Cancer Australia Priority-driven Collaborative Cancer Research Scheme and Varian.

Le texte complet de cet article est disponible en PDF.

Plan


© 2026  Elsevier Ltd. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 27 - N° 6

P. 711-720 - juin 2026 Retour au numéro
Article précédent Article précédent
  • [177Lu]Lu-dota-tate versus sunitinib in patients with metastatic progressive neuroendocrine tumours of the pancreas (OCLURANDOM): a randomised, controlled, phase 2 trial
  • Eric Baudin, Alice Durand, Amandine Beron, Denis Smith, Désirée Déandreis, David Taieb, Catherine Ansquer, Lawrence Dierickx, Emmanuel Deshayes, Olivia Hentic, Salma Moalla, Yves Menu, Rachida Lebtahi, Eric Assenat, Yann Touchefeu, Rosine Guimbaud, Laetitia Dahan, Livia Lamartina, Nadir Cheurfa, Elske Quak, Karine Bouhier-Leporrier, Magalie Haissaguerre, Elif Hindie, Christine Do Cao, Catherine Lombard-Bohas, Arnaud Jannin, Thomas Walter, Michel Ducreux, Sarah Chaib, Julien Hadoux, Stephanie Foulon
| Article suivant Article suivant
  • Ultra-hypofractionated stereotactic ablative body radiotherapy for primary renal cell carcinoma: 5-year outcomes from a pooled analysis of the FASTRACK trials
  • Shankar Siva, Muhammad Ali, Nicholas Hardcastle, Tomas Kron, Braden Higgs, Farshad Foroudi, Jeremy Ruben, Sree Appu, Jarad Martin, Swetha Sridharan, Rebecca Montgomery, Ryan Davey, Charles Lin, Mark Shaw, Sarat Chander, Mark Sidhom, Ben G L Vanneste, Declan G Murphy, Nathan Lawrentschuk, David Pryor, Simon Wood, Daniel Moon, Mathias Bressel

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Elsevier s'engage à rendre ses eBooks accessibles et à se conformer aux lois applicables. Compte tenu de notre vaste bibliothèque de titres, il existe des cas où rendre un livre électronique entièrement accessible présente des défis uniques et l'inclusion de fonctionnalités complètes pourrait transformer sa nature au point de ne plus servir son objectif principal ou d'entraîner un fardeau disproportionné pour l'éditeur. Par conséquent, l'accessibilité de cet eBook peut être limitée. Voir plus

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2026 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.